From the FDA Drug Label
Trihexyphenidyl HCl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. The role of Artane (Trihexyphenidyl) in treating chorea is not explicitly stated in the drug label.
- The label mentions treatment of parkinsonism and extrapyramidal disorders, but does not directly address chorea. 1
From the Research
Artane (trihexyphenidyl) is not the first-line treatment for chorea, and its use should be considered on a case-by-case basis, taking into account the underlying cause of the chorea and the potential side effects of the medication. Chorea is a complex movement disorder that can result from a variety of conditions, and the treatment approach should be tailored to the individual patient's needs [2]. The mainstay of treatment for secondary chorea is addressing the underlying causative disorder, and symptomatic treatment should be based on the functional impact of the chorea on the patient [3, 4].
When considering the use of Artane (trihexyphenidyl) for chorea, it is essential to weigh the potential benefits against the potential risks and side effects. Artane works by blocking acetylcholine receptors in the brain, which can help reduce abnormal nerve signals causing involuntary movements [2]. However, it is not without side effects, which can include dry mouth, blurred vision, constipation, urinary retention, and confusion, particularly in elderly patients [2].
Other medications, such as tetrabenazine, deutetrabenazine, or antipsychotics, may be preferred for certain types of chorea, particularly Huntington's disease-related chorea [2, 5]. Tetrabenazine, for example, is a monoamine-depleting agent that has been shown to be effective in reducing chorea in patients with Huntington's disease [5]. Olanzapine, an antipsychotic medication, has also been reported to improve chorea in patients with Huntington's disease [6].
In summary, while Artane (trihexyphenidyl) may be used to treat chorea in certain cases, it is not the first-line treatment, and its use should be carefully considered in the context of the individual patient's needs and the potential side effects of the medication [3, 4, 2]. Treatment should be monitored regularly, with dose adjustments based on symptom control and side effects [2].